It was suggested that LILRB2 exerted a critical role in the maturation of macrophages; antagonism of LILRB2 with specific monoclonal antibodies could impair the inhibitory effect of macrophages on T cell proliferation, reduce the infiltration of MDSCs and Tregs in tumor tissue, enhance the phagocytosis by macrophages, reprogram TAMs to a proinflammatory phenotype and promote antitumor immunity (133). Here, LILRB2 is linked to neoplasm.